Ilpez

Itraconazole, the active ingredient in Ilpez, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis and aspergillosis in adult patients.\n\nGNH India supplies Ilpez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilpez (itraconazole) is employed to manage fungal infections that affect the skin, nails and internal organs.\n\nDermatophytosis: reduces fungal growth and clears skin lesions.\nOnychomycosis: eradicates nail‑bed infection and promotes healthy nail regrowth.\nBlastomycosis: eliminates systemic blastomyces organisms and resolves pulmonary symptoms.\nHistoplasmosis: treats disseminated histoplasma infection and prevents disease progression.\nAspergillosis: controls invasive aspergillus infection in immunocompromised patients.

Common Side Effects:\n- Nausea: mild to moderate stomach upset.\n- Headache: transient cranial discomfort.\n- Abdominal pain: cramping or discomfort in the stomach area.\n- Rash: skin irritation or mild erythema.\n- Taste disturbance: altered or reduced sense of taste.\n- Diarrhea: loose stools occurring occasionally.\n\nSerious or Rare Side Effects:\n- Hepatotoxicity: elevated liver enzymes or liver injury.\n- Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Cardiac failure: worsening of pre‑existing heart conditions.\n- QT prolongation: potential arrhythmia risk.\n- Severe liver injury: jaundice, hepatic failure requiring medical attention.

Before initiating therapy, clinicians should consider several safety measures.\n\nAssess liver function: obtain baseline hepatic enzymes and monitor periodically.\nMonitor drug interactions: review concomitant medications that affect CYP3A4 metabolism.\nAvoid use in patients with known hypersensitivity: discontinue if allergic reactions occur.\nUse caution in patients with heart failure: monitor cardiac status closely.\nStore at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Itraconazole has several notable drug interactions that require attention.\n\nMajor Interactions (Avoid):\n- Rifampin: markedly reduces itraconazole plasma levels, compromising efficacy.\n- Ketoconazole: additive hepatotoxic risk when combined.\n- St. John's wort: induces metabolism, lowering itraconazole exposure.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may increase INR, necessitating closer coagulation monitoring.\n- Fluconazole: can raise itraconazole concentrations, requiring dose adjustment.\n- Carbamazepine: may decrease itraconazole levels, potentially reducing therapeutic effect.